Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

05 Aug 2026 - 07 Aug 2026
18 Aug 2026 - 20 Aug 2026

An Experimental Analgesic Is More Potent Than Morphine

By HospiMedica International staff writers
Posted on 10 Jan 2011
A new study describes morphine-6-0-sulfate, which although having a similar chemical structure to standard morphine, is potentially more potent, longer lasting, and less likely to cause constipation than standard morphine.

Researchers at Loyola University (Chicago, IL, USA) and the University of Kentucky (Lexington, USA) characterized the relatively little-known morphine derivative using a range of well-established rodent pain models, demonstrating that morphine-6-O-sulfate was efficacious using several routes of administration, including neuroaxial (injected into the intrathecal space), parenteral (injection into the peritoneum), and oral administration. More...
The drug showed potent, dose-related, analgesic activities against acute nociceptive pain (using the tail flick test), neuropathic pain (under chronic constriction nerve injury hyperalgesia and allodynia), and inflammatory pain (using the formalin test).

Morphine-6-0-sulfate maintained its maximum effect for three hours, compared with one-and-a-half hours for standard morphine. It also took the rats 25 days to build tolerance to morphine-6-0-sulfate, compared with 10 days with standard morphine. Morphine-6-0-sulfate was also more potent than standard morphine for neuropathic and inflammatory pain. The researchers did find that morphine-6-0-sulfate could cause constipation, but only at doses 10 to 20 times higher than the effective doses. Morphine-6-0-sulfate also had a good separation based on dose (at least 10-fold) between side effects and analgesia in all models of pain tested. In addition, morphine-6-O-sulfate had a more favorable potency ratio for delay of gastrointestinal transit and analgesia, when compared to morphine. The study was published in the December 2010 issue of the European Journal of Pharmacology.

"These preclinical findings suggest that morphine-6-O-sulfate is a potential candidate for development as a novel opioid for management of nociceptive, neuropathic, and mixed pain states,” said lead author Joseph Holtman, MD, PhD, and colleagues of the departments of anesthesiology and molecular pharmacology and therapeutics.

Related Links:
Loyola University
University of Kentucky



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Patient Monitoring System
AlarmSense
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.